Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BioAtla (BCAB) Stock Price & Analysis
187 Followers
BCAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.24 - $4.02
Previous Close$3.1
Volume668.69K
Average Volume (3M)644.16K
Market Cap
$144.35M
Enterprise Value$70.45M
Total Cash (Recent Filing)$80.63M
Total Debt (Recent Filing)$1.92M
Price to Earnings (P/E)-1.2
Beta2.70
Next Earnings
Aug 08, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding48,115,918
10 Day Avg. Volume788,039
30 Day Avg. Volume644,161
Standard Deviation0.36
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.78
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$10.67Price Target Upside244.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
BioAtla News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBioAtla outlines plans to advance BA3011 towards commercialization with two potential registrational paths, indicating significant progress in the drug's development.
Drug EfficacyBioAtla's BA3011 has demonstrated a 17% objective response rate in previously treated NSCLC patients, with responses lasting an average of 4.8 months.
Financial OutlookAnalyst maintains a Market Outperform rating with a price target of $12 on BioAtla, suggesting a strong future performance based on financial analyses.
Bears Say
Clinical TrialsThe number of active ADCs in NSCLC is small, and recent developments have been disappointing.
Drug EfficacyThe nivolumab combination cohort showed lower efficacy compared to the monotherapy cohort, likely due to the enrollment of more heavily pretreated patients.
Risk FactorsRisk factors for the stock include clinical, commercial, collaboration, dilution, and legal and intellectual property concerns.
---
Ownership Overview
24.00% Insiders
12.03% Mutual Funds
29.32% Other Institutional Investors
34.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $1.24 and its highest was $4.02 in the past 12 months.
What is BioAtla’s market cap?
Currently, no data Available
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on May 14, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.542 by $0.062.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -$0.47.
How many shares outstanding does BioAtla have?
BioAtla has 48,115,917 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.542. Following the earnings report the stock price went up 14.943%.
Which hedge fund is a major shareholder of BioAtla?
Among the largest hedge funds holding BioAtla’s share is Perceptive Advisors LLC. It holds BioAtla’s shares valued at 180K.
---
BioAtla Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (244.19% Upside)
$10.67 (244.19% Upside)
Hedge Fund Trend
Increased
By 84.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.48%
12-Months-Change
Fundamentals
Return on Equity
-115.68%
Trailing 12-Months
Asset Growth
-56.39%
Trailing 12-Months
Company Description
BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
---
BCAB Earnings Call
Q1 2024
0:00 / 0:00
---
BCAB Stock 12 Month Forecast
Average Price Target
$10.67
▲(244.19% Upside)
Technical Analysis
Best Analysts Covering BCAB
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-3.55%
reiterated a buy rating 2 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -3.55% per trade.
---